$NBIX · NEUROCRINE BIOSCIENCES INC
Neurocrine Biosciences reported Q3 FY2026 revenue of $1.123B (+41.2% YoY), driven by INGREZZA ($801.5M), CRENESSITY ($210.8M), and newly acquired VYKAT XR ($106.7M). Net income was $206.5M with diluted EPS of $1.96, pressured by a $52.3M unrealized loss on equity investments. The balance sheet reflects the May 2026 Soleno acquisition, which added $2.24B in intangible assets and $494.6M in goodwill.
- Q3 total revenues hit $1.123B, up 41.2% YoY from $794.9M
- INGREZZA net product sales reached $801.5M in Q3, up from $686.6M a year ago
- CRENESSITY net product sales more than doubled to $210.8M vs $98.1M in Q3 2025
- VYKAT XR contributed $106.7M in Q3 following the May 2026 Soleno acquisition
- Q3 diluted EPS of $1.96 vs $2.04 a year ago, weighed by $52.3M unrealized loss on equity investments
Extended-hours trading shows NBIX at $154.00, up 5.95% from the regular close of $145.35, indicating strong positive reaction to the 41% revenue surge and CRENESSITY/VYKAT XR momentum.
Neurocrine is transitioning from an INGREZZA-dependent story to a three-product rare-disease powerhouse, with CRENESSITY and VYKAT XR now contributing 28% of Q3 net product sales.
Neurocrine's rare-disease portfolio now spans three commercial products — INGREZZA (tardive dyskinesia/Huntington's chorea), CRENESSITY (CAH), and VYKAT XR (Prader-Willi syndrome) — diversifying beyond its legacy INGREZZA franchise.
The Soleno acquisition added $2.24B in intangible assets and $494.6M in goodwill; purchase price allocation remains preliminary and subject to measurement-period adjustments. A $52.3M unrealized loss on equity investments hit Q3 other income, creating earnings volatility.